Boundless Bio to Present at the Guggenheim Oncology Conference

via Business Wire
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually. Presentation details are as follows:

Date: Friday, February 11, 2022

Time: 2:00 PM – 2:25 PM EST

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article